Harpoon Therapeutics, Inc.
(NASDAQ CM: HARP)
Rigrodsky Law, P.A. is investigating Harpoon Therapeutics, Inc. (“Harpoon”) regarding possible breaches of fiduciary duties and other violations of law related to Harpoon’s agreement to be acquired by Merck. Under the terms of the agreement, Harpoon shareholders will receive $23.00 per share in cash.